Anti-PD-L1 showed the lowest tumor recurrence rate (15%) compared with anti-IL-6R (57%) and IgG 2b, κ (90%), but anti-IL-6R proved a better anti-metastasis outcome (31%) than anti-PD-L1 (44%) and IgG 2b, κ (50%) (Figure 5I). The gene discussed is IL6R; the disease is neoplasm.